Mesoblast Stock Today
| MESO Stock | USD 5.17 0.20 3.72% |
Performance13 of 100
| Odds Of DistressLess than 36
|
Mesoblast is selling at 5.17 as of the 15th of April 2024; that is -3.72 percent decrease since the beginning of the trading day. The stock's open price was 5.37. Mesoblast has about a 36 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Mesoblast are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of March 2024 and ending today, the 15th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of November 2015 | Category Healthcare | Classification Health Care |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 101.48 M outstanding shares of which 2.34 M shares are now shorted by private and institutional investors with about 0.48 trading days to cover. More on Mesoblast
Moving against Mesoblast Stock
| 0.7 | BIIB | Biogen Inc Financial Report 23rd of April 2024 | PairCorr |
| 0.65 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.64 | JNJ | Johnson Johnson Earnings Call Tomorrow | PairCorr |
| 0.53 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 23rd of May 2024
Mesoblast Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Mesoblast's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mesoblast or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Executive Director | Silviu Itescu | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Mesoblast report their recommendations after researching Mesoblast's financial statements, talking to executives and customers, or listening in on Mesoblast's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Mesoblast. The Mesoblast consensus assessment is calculated by taking the average forecast from all of the analysts covering Mesoblast. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Mesoblast's liquidity, profitability, solvency, and operating efficiency, Mesoblast is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Mesoblast is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mesoblast's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Mesoblast's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mesoblast's financial leverage. It provides some insight into what part of Mesoblast's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mesoblast (MESO) is traded on NASDAQ Exchange in USA. It is located in 55 Collins Street, Melbourne, VIC, Australia, 3000 and employs 83 people. Mesoblast is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 570.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mesoblast's market, we take the total number of its shares issued and multiply it by Mesoblast's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Mesoblast conducts business under Biotechnology sector and is part of Health Care industry. The entity has 101.48 M outstanding shares of which 2.34 M shares are now shorted by private and institutional investors with about 0.48 trading days to cover.
Mesoblast currently holds about 85.5 M in cash with (63.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Check Mesoblast Probability Of Bankruptcy
Ownership AllocationMesoblast maintains a total of 101.48 Million outstanding shares. Roughly 99.0 % of Mesoblast outstanding shares are held by general public with 0.74 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mesoblast Ownership Details
Mesoblast Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Mesoblast jumping above the current price in 90 days from now is nearly 4.82%. The Mesoblast probability density function shows the probability of Mesoblast stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0187. This indicates Mesoblast market returns are highly reactive to returns on the market. As the market goes up or down, Mesoblast is expected to follow. Moreover, mesoblast has an alpha of 1.93, implying that it can generate a 1.93 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Mesoblast to move above the current price in 90 days from now is nearly 4.82 (This Mesoblast probability density function shows the probability of Mesoblast Stock to fall within a particular range of prices over 90 days) .
Mesoblast Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Mesoblast that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mesoblast's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mesoblast's value.| Instituion | Recorded On | Shares | |
| Rhumbline Advisers | 2023-09-30 | 17.3 K | |
| Chapin Davis Inc | 2023-09-30 | 17 K | |
| Lpl Financial Corp | 2023-09-30 | 12.9 K | |
| Diligent Investors, Llc | 2023-09-30 | 12.5 K | |
| Aries Wealth Management | 2023-09-30 | 10 K | |
| Blue Zone Wealth Advisors, Llc | 2023-09-30 | 10 K | |
| Institutional & Family Asset Management, Llc | 2023-09-30 | 3 K | |
| Compagnie Lombard, Odier Sca | 2023-09-30 | 2 K | |
| Gamma Investing Llc | 2023-12-31 | 690 | |
| Penbrook Management Llc | 2023-12-31 | 275.4 K | |
| Susquehanna International Group, Llp | 2023-09-30 | 92.4 K |
Mesoblast Historical Income Statement
Mesoblast Income Statement is one of the three primary financial statements used for reporting Mesoblast's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Mesoblast revenue and expense. Mesoblast Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Mesoblast's Depreciation And Amortization is very stable compared to the past year. As of the 15th of April 2024, Interest Expense is likely to grow to about 23.5 M, while Selling General Administrative is likely to drop about 20.2 M. View More FundamentalsMesoblast Stock Against Markets
Picking the right benchmark for Mesoblast stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Mesoblast stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Mesoblast is critical whether you are bullish or bearish towards Mesoblast at a given time. Please also check how Mesoblast's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mesoblast without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Mesoblast Corporate Directors
Mesoblast corporate directors refer to members of a Mesoblast board of directors. The board of directors generally takes responsibility for the Mesoblast's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Mesoblast's board members must vote for the resolution. The Mesoblast board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Shawn Tomasello | Director | Profile | |
| Michael Spooner | Non-Executive Independent Director | Profile | |
| BenZion Weiner | Non-Executive Independent Director | Profile | |
| Donal ODwyer | Non-Executive Independent Director | Profile |
How to buy Mesoblast Stock?
Before investing in Mesoblast, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Mesoblast. To buy Mesoblast stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Mesoblast. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Mesoblast stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Mesoblast stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Mesoblast stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Mesoblast, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Mesoblast Stock please use our How to Invest in Mesoblast guide.
Already Invested in Mesoblast?
The danger of trading Mesoblast is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Mesoblast is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Mesoblast. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Mesoblast is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Mesoblast Stock analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Mesoblast's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 0.09 | Quarterly Revenue Growth (0.12) | Return On Assets (0.06) | Return On Equity (0.14) |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.